Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Adult Congenital Heart Disease
What hemodynamic, clinical, and/or EKG parameters do you consider when recommending ICD implantation for patients with repaired Tetralogy of Fallot?
Related Questions
How do you manage asymptomatic non-sustained atrial arrhythmia in patients with single ventricle and Fontan physiology?
Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?
What are first-line choices for vasopressors/inotropes to use in hypotensive patients with Eisenmenger Syndrome?
When would you consider genetic screening of first-degree relatives in patients with bicuspid aortic valves?
What has been your stepwise approach to oxygenation, including when to consider the use of inhaled nitric oxide or epoprostenol, in refractory hypoxemia due to cardiogenic pulmonary edema in patients who are otherwise not ECMO candidates?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
Are there any heightened risks for cardioversion following a recent PCI from a stent patency standpoint or hemodynamic concerns?
How do you approach the management of aortic stenosis in an elderly, frail patient with multiple comorbidities who is symptomatic but considered high risk for surgical aortic valve replacement?
What is a reasonable class of antihypertensive to start in patients with HCM who remain hypertensive and symptomatic in spite of maximal doses of beta blockade or calcium channel blockers?
